Putnam BioRevolution ETF
Data updated: 2025-12-29
C000237308 — Putnam BioRevolution ETF data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Large Cap Growth Equity · $4.66M AUM · 0.70% expense ratio · -0.6% 1-yr return. From SEC regulatory filings.
C000237308 Fund Overview
Putnam BioRevolution ETF is a US mutual fund managed by Putnam ETF Trust, categorised as United States Large Cap Growth Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Putnam ETF Trust
- Category: United States Large Cap Growth Equity
- Assets under management: $4.66M
- 1-year return: -0.6%
- SEC CIK: 0001845809
- SEC series ID: S000077138
- Share class ID: C000237308
C000237308 Holdings
Top 10 holdings of Putnam BioRevolution ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Thermo Fisher Scientific Inc | 9.18% |
| AbbVie Inc | 5.37% |
| NVIDIA Corp | 5.14% |
| Corteva Inc | 4.89% |
| Bio-Rad Laboratories Inc | 4.77% |
| Putnam Government Money Market Fund | 4.76% |
| Ascendis Pharma A/S | 4.69% |
| Novonesis Novozymes B | 4.54% |
| AstraZeneca PLC | 4.46% |
| Eli Lilly & Co | 3.94% |
C000237308 Portfolio Allocation
Asset-class allocation of Putnam BioRevolution ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 95.2% |
| Cash & Equivalents | 4.8% |
C000237308 Performance
Total returns for C000237308 (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| 1 year | -0.6% |
| 3 years (annualised) | 7.0% |
C000237308 Risk Information
Risk metrics for C000237308, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 12.2%
C000237308 Costs and Fees
C000237308 costs about $70 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.70%
- Gross expense ratio: 0.70%
- Portfolio turnover: 32%
- Brokerage commissions: 1.07 bps of average net assets (SEC N-CEN)
C000237308 Cashflows
Over the 12 months to 2025-10, Putnam BioRevolution ETF had net outflows of $791.88K, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2025-10 | −$791.88K |
| 2025-09 | $0 |
| 2025-08 | $0 |
| 2025-07 | $0 |
| 2025-06 | $0 |
| 2025-05 | $0 |
C000237308 Debt Constituents
No individual debt constituents are reported in Putnam BioRevolution ETF's latest SEC N-PORT filing.
C000237308 Prospectus and SEC Filings
Official Putnam BioRevolution ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Large Cap Growth Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.